Thalidomide in the treatment of multiple myeloma

References

• Bataille R, Harousseau JL. Multiple myeloma. N. Engl. Med 336,1657–1664 (1997).
   PubMed Web of Science ®Google Scholar
• •Concise review of multiple myeloma.
   Google Scholar
• Greenlee RE Hill-Harmon MB, Murray T, Thun M. Cancer Statistics. CA Cancer 1 Clin. 51,15–36 (2001).
   Google Scholar
• Kyle RA. 'Benign' monoclonal gammopathy after 20 to 35 years of follow-up. Mayo Clin. Proc. 68,26-36 (1993).
   Google Scholar
• ••The definitive study describing the naturalhistory of monoclonal garnrnopathy of undetermined significance.
   Google Scholar
• Greipp PR, Kyle RA. Staging, kinetics and prognosis of multiple myeloma. In: Neoplastic Diseases of the Blood. Wiemik PH, Canellos GP, Dutcher JP, Kyle RA. (Eds.), Churchill Livingstone, New York, USA, 537–559 (1996).
   Google Scholar
• Myeloma Trialists' Collaborative Group. chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. j Clin. Oncol 16,3832–3842 (1998).
   Google Scholar
• •Key study that shows lack of superiority of various standard dose combination chemotherapy regimes to oral melphalan-prednisone therapy in multiple myeloma.
   Google Scholar
• Kovacsovics T, Delaly A. Intensive strategies in myeloma. Semin. Hematol 34,49–60 (1997).
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos M. The of multiple myeloma. N Engl. Med. 330, 484–489 (1994).
   PubMed Web of Science ®Google Scholar
• Oken MM, Harrington DP, Abramson N, RA, Knospe W, Glick JH. of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer 79, 1561–1567 (1997).
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M. The role of hematopoietic stem cell in multiple myeloma. Semin. Hematol 34,61–66 (1997).
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Epstein J et al and therapy of multiple myeloma 1996. Semin. Hematol 34, 67–72 (1997).
   Google Scholar
• Gertz MA, Pineda AA, Chen MG et al. and relapsing multiple myeloma treated by blood stem cell transplantation. Am. Med Sc]. 309, 152–161 (1995).
   PubMedGoogle Scholar
• Attal M, Harousseau JL, Stoppa AM et al prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl. . 335, 91–97 (1996).
   PubMed Web of Science ®Google Scholar
• ••This randomized trial established thesuperiority of autologous stem cell transplantation to conventional chemotherapy in the treatment of newly diagnosed myeloma.
   Google Scholar
• Fermand JP, Ravaud P, Chevret S et al. versus late high dose therapy (HDT) and autologous peripheral blood stem cell transplantation in multiple myeloma (MM): Results of a prospective randomized trial. B/ooc/88\(Suppl. 1), 685a (1996).
   Google Scholar
• Facon T, Mary JY, Harousseau JL et al. -line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM). Preliminary results of a prospective randomized trial (CIAM) protocol. Blood 88\(Suppl. 1), 685a (1996).
   Google Scholar
• Bensinger WI, Buckner CD, Anasetti C etal. marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. fliooc188, 2787–2793 (1996).
   Google Scholar
• Cavo M, Bandini G, Benni M et al. -dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone Marrow Transplant. 22, 27–32 (1998).
   PubMedGoogle Scholar
• Molina A, Sahebi F, Maloney DG et al. -myeloablative peripheral blood stem cell (PBSC) allografts following cytoreductive autotransplants for treatment of multiple myeloma (MM). Blood 96, 480a(A2063) (2000).
   Google Scholar
• Lokhorst HM, Schattenberg A, Comelissen, Thomas LL, Verdonck LE Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90, 4206–4211 (1997).
   PubMed Web of Science ®Google Scholar
• Oken MM, Leong T, Lenhard RE, Jr. et al. addition of interferon or high dose to standard in the treatment of patients with multiple myeloma: Phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer86, 957–968 (1999).
   PubMed Web of Science ®Google Scholar
• Shustik C. Interferon in the treatment of myeloma. Cancer ControI5, 226–234 (1998).
   PubMedGoogle Scholar
• Mandelli F, Avvisati G, Amadori S et al. treatment with recombinant interferon a-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl. I Med. 322, 1430–1434 (1990).
   Google Scholar
• Browman GP, Bergsagel D, Sicheri D et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. j Clin. Oncol 13, 2354–2360 (1995).
   PubMed Web of Science ®Google Scholar
• Westin J, Rodjer S, Turesson I, Cortelezzi A, M, Zador G. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group. Br J. Thematol 89, 561–568 (1995).
   Google Scholar
• Salmon SE, Crowley JJ, Grogan TM, Finley, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J. Clin. Oncol 12, 2405–2414 (1994).
   PubMed Web of Science ®Google Scholar
• Peest D, Deicher H, Coldewey R et al.. A of polychemotherapy and melphalan/prednisone for primary remission induction and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur j Cancer 2, 146–151 (1995).
   Google Scholar
• Ludwig H, Cohen AM, Polliack A et al. -a for induction and in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann. Oncol 6, 467–476 (1995).
   PubMed Web of Science ®Google Scholar
• Kyle RA. The role of bisphosphonates in myeloma. Ann. Intern Med. 132, 734–736 (2000).
   PubMed Web of Science ®Google Scholar
• Berenson JR, Lichtenstein A, Porter L et al.. of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl. I Med. 334, 488–493 (1996).
   PubMed Web of Science ®Google Scholar
• Berenson JR, Lichtenstein A, Porter L et al.. -term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. j Clin. Oncol 16, 593–602 (1998).
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Roncali L et al. Bone angiogenesis and progression in multiple myeloma. BE j Haematol 87, 503–508 (1994).
   PubMed Web of Science ®Google Scholar
• •This was the first study to demonstrate increased bone marrow angiogenesis in myeloma.
   Google Scholar
• Rajkumar SV, Fonseca R, Witzig TE, Gertz, Greipp PR Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 13, 469–472 (1999).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Leong T, Roche PC eta]@. value of bone marrow angiogenesis in multiple myeloma. Clin. Cancer Res. 6, 3111–3116 (2000).
   Google Scholar
• •This is the first published report demonstrating the prognostic value of angiogenesis in myeloma.
   Google Scholar
• Fakrnan J. Seminars in Medicine of the Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl. Med 333, 1757–1763 (1995).
   Google Scholar
• •Excellent and important review of tumor angiogenesis by the pioneering investigator in this field.
   Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sc]. USA 91, 4082–4085 (1994).
   PubMed Web of Science ®Google Scholar
• ••This important study established theantiangiogenic properties of thalidomide.
   Google Scholar
• Singhal S, Mehta J, Desikan R et al. activity of thalidomide in refractory multiple myeloma. N Engl. Med. 341, 1565–1571 (1999).
   PubMed Web of Science ®Google Scholar
• ••This landmark paper established theactivity of thalidomide in refractory multiple myeloma.
   Google Scholar
• Rajkumar SV, Witzig TE. A review of and anti-angiogenic therapy with thalidomide in multiple myeloma. Cancer Treat. Rev. 26, 351–362 (2000).
   PubMed Web of Science ®Google Scholar
• Lenz W Thalidomide and congenital . Lancetl, 45 (1962).
   Google Scholar
• McBride WG. Thalidomide and congenital . Lancet2, 1358 (1961).
   Web of Science ®Google Scholar
• Argiles JM, Carbo N, Lopez-Soriano FJ. tumour necrosis factor-a responsible for the fetal malformations associated with thalidomide in the early 1960s? Med. 50, 313–318 (1998).
   Google Scholar
• Parman T, Wiley MJ, Wells PG. Free radical- oxidative DNA damage in the mechanism of thalidomide teratogenicity. Natum Med. 5, 582–585 (1999).
   Google Scholar
• •This study provides a mechanism for the teratogenicity of thalidomide.
   Google Scholar
• Iyer CG, Languillon J, Ramanujam K eta]. co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull. WHO 45, 719–732 (1971).
   Google Scholar
• Olson KB, Hall TC, Horton J, Khung CL, HE Thalidomide (N- ) in the treatment of advanced cancer. Clin. Pharmacol Ther. 6, 292–297 (1965).
   PubMed Web of Science ®Google Scholar
• Grabstad H, Golbey R. Clinical experience with thalidomide in patients with cancer. Clin. Pharmacol Ther. 6, 298–302 (1965).
   PubMed Web of Science ®Google Scholar
• Stirling DI. Pharmacology of thalidomide. . Hematol 37, 5–14 (2000).
   Google Scholar
• •Easy to read, excellent review of the pharmacology of thalidomide.
   Google Scholar
• Fine HA, Figg WD, Jaeckle K eta]. A Phase trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas. j Gun. Oncol 18, 708–715 (2000).
   Google Scholar
• Rajkumar SV. Thalidomide in multiple . Oncology 14\(Suppl. 13), 11–15 (2000).
   Google Scholar
• Raje N, Anderson K. Thalidomide-a revival . N Engl. Med. 341, 1606–1607 (1999).
   PubMed Web of Science ®Google Scholar
• Kenyon BM, Browne F, D'Amato RJ. Effects thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 64, 971–978 (1997).
   Google Scholar
• Or R, Feferman R, Shoshan S. Thalidomide vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Exp. Hy-natal 26, 217–221 (1998).
   Google Scholar
• Minchinton Al, Fryer IKH, Wendt KR, Clow, Hayes MM. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs7, 339–343 (1996).
   Google Scholar
• Bauer KS, Dixon SC, Figg WD. Inhibition angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol 55, 1827–1834 (1998).
   Google Scholar
• Rajkumar SV, Fonseca R, Dispenzieri A et A Phase II trial of thalidomide in the treatment of relapsed multiple myeloma (IVIM) with laboratory correlative studies. B/ooc/96, 168a (A723) (2000).
   Google Scholar
• Rajkumar SV, Hayman S, Fonseca R et al plus dexamethasone (Thal/ Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM). B/ooc/96, 168a (A722) (2000).
   Google Scholar
• Kumar S, Fonseca R, Dispenzieri A et al. marrow (BM) angiogenesis in multiple myeloma (MM): effect of therapy and prognostic value. Blood 96, 363a (A1567) (2000).
   Google Scholar
• Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith IKA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mRNA degradation. I Exp Med. 177, 1675–1680 (1993).
   PubMed Web of Science ®Google Scholar
• Turk BE, Jiang H, Liu JO. Binding of to al-acid glycoprotein may be involved in its inhibition of tumor necrosis factor a production. Proc. Nati Acad. Sc]. USA 93, 7552–7556 (1996).
   Google Scholar
• Haslett PA, Corral LG, Albert M, Kaplan G. costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. J. Exp. Med. 187, 1885–1892 (1998).
   Google Scholar
• McHugh SM, Rifkin IR, Deighton J et al. immunosuppressive drug thalidomide induces T helper cell Type 2 (Th2) and concomitantly inhibits Thl cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin. Exp. Immunol 99, 160–167 (1995).
   Google Scholar
• Geitz H, Handt S, Zwingenberger K. selectively modulates the density of cell surface molecules involved in the adhesion cascade. immunopharmaca 31, 213–221 (1996).
   Google Scholar
• Zeldis JB, Williams BA, Thomas SD, ME. STEPS: a comprehensive program for controlling and monitoring access to thalidomide. Clin. Ther. 21, 319–330 (1999).
   PubMed Web of Science ®Google Scholar
• Barlogie B. Thalidomide (T) in the of multiple myeloma (MM) : The Arkansas Experience in > 300 patients (Pts) with single agent (SA) and combination chemotherapy (CT). Proc. Am. Soc. Clin. Oncol 19, 9a (A28) (2000).
   Google Scholar
• Barlogie B, Spencer T, Tricot G etal. Long follow up of 169 patients receiving a Phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). B/ooc/96, 514a (A2213) (2000).
   Google Scholar
• Rajkumar SV, Fonseca R, Dispenzieri A et Thalidomide in the treatment of relapsed and refractory myeloma. Blood 94\(Suppl. 1), 316a (A1414) (1999).
   Google Scholar
• Rajkumar SV, Fonseca R, Dispenzieri A et Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin. Proc. 75, 897–902 (2000).
   PubMed Web of Science ®Google Scholar
• Yakoub-Agha I, Attal M, Dumontet C et al. in patients with advanced myeloma: survival prognostic factors. Blood 96, 167a (A718) (2000).
   Google Scholar
• Weber DM, Gavino M, Delasalle K, Rankin K, Giralt S, Alexanian R. Thalidomide alone or with dexamethasone for multiple myeloma. B/ooc/ 94 (Suppl. 1), 604a (A 2686) (1999).
   Google Scholar
• Raza SN, Veksler Y, Sabir T, Li Z, Anderson, Jagannath S. Durable response to thalidomide in relapsed/refractory multiple myeloma (MM). B/ooc/96, 168a (A726) (2000).
   Google Scholar
• Dune BGM, Stepan DE. Efficacy of low thalidomide ('T) in multiple myeloma. B/ooc/94\(Suppl. 1), 316a (A 1413) (1999).
   Google Scholar
• Juliusson G, Celsing F, Turesson I, Lenhoff S, M, Maim C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. BEI 112ernatol. 109, 89–96 (2000).
   Google Scholar
• Kneller A, Raanani P, Hardan I et a/. Therapy thalidomide in refractory multiple myeloma — the revival of an old drug. BEI 112ernatol. 108, 391–393 (2000).
   Google Scholar
• Shima Y, Treon SP, Yoshizaki K et al. Clinical biological activity of thalidomide (THAL) in multiple myeloma (MM). B/ooc/ 94\(Suppl. 1), 125a (A 549) (1999).
   Google Scholar
• Neben K, Hawighorst H, Moehler TM et Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters. B/ooc/94\(Suppl. 1), 124a (A545) (1999).
   Google Scholar
• Weber DM, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide with dexamethasone for resistant multiple myeloma. Blood 96, 167a (A719) (2000).
   Google Scholar
• Barlogie B, Desikan R, Munshi N et al. course DT PACE anti- effects CR in plasma cell leukemia and fulminant multiple myeloma (MM). B/ooc/92\(Suppl. 1), 273b (A 4180) (1998).
   Google Scholar
• Munshi N, Desikan R, Zangari M et al. with DT-PACE for previously treated multiple myeloma. Blood 94\(Suppl. 1), 123a (A 540) (1999).
   Google Scholar
• Coleman M, Leonard JP, Nahum K. Non- therapy with BLT-D (Biaxin®, low dose thalidomide and dexamethasone) is highly active in Waldenstrorris macroglobulinemia and myeloma. B/ooc/96, 167a (A720) (2000).
   Google Scholar
• Rajkumar SV, Gertz MA, Witzig TE. Life- toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl. Med. 343, 972–973 (2000).
   PubMed Web of Science ®Google Scholar
• Weber DM, Rankin K, Gavin° M et al. factors and sensitivity to thalidomide in previously untreated myeloma. Blood 96, 168a(A724) (2000).
   Google Scholar
• Rajkumar SV. The current status of in the treatment of cancer. Oncology (2001) (In Press).
   Google Scholar